UK-based clinical-stage biotechnology company TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced on Monday shareholder approval of a 25% stock dividend during its General Meeting.
The special dividend grants 0.25 American Depositary Shares (ADSs) for each ADS held on the record date of 2 January 2025, with delivery anticipated by 6 January 2025.
Trading in TC BioPharm's ADSs will pause at 17:00 hours on 2 January 2025, per Nasdaq requirements, resuming around 8 January 2025, to facilitate the dividend process. Nasdaq plans to adjust the opening price on 8 January to account for dilution from the dividend issuance.
Perrigo increases quarterly dividend
AbbVie announces quarterly cash dividend
hVIVO acquires German Clinical Research Units for EUR10m; Targets earnings growth by 2026
OptiBiotix expands into Indian market with Amazon launch
Poxel to receive royalties and sales-based payment from Sumitomo Pharma
ReciBioPharm secures grant to expand RNA manufacturing in LMICs
CVS Health to pays common stock quarterly dividend of USD0.665 per share
TC BioPharm receives shareholders' approval for 25% stock dividend
USANA Health Sciences acquires controlling stake in Hiya Health for USD205m
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
Abbott announces dividend increase and 53 years of growth
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Moberg Pharma's MOB-015 fails to meet primary endpoint in phase 3 study
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine